|
| Status |
Public on Jul 12, 2012 |
| Title |
693T1 |
| Sample type |
RNA |
| |
|
| Source name |
Tumor
|
| Organism |
Mus musculus |
| Characteristics |
tissue: Tumor
strain: C57BL/6
age: 48 weeks
treatment: BEZ235
|
| Treatment protocol |
At ~44 weeks of age, the animals (n=9-10) were gavaged twice daily for 28 days with the specified doses of RAD001 and/or BEZ235. The mice were starved for three hours prior to sacrifice and received their last dose of RAD001 at the time starvation or BEZ235 1 hour before sacrifice.
|
| Growth protocol |
C57Bl/6 mice were obtained from Jackson laboratories. At two weeks of age, male mice were injected intraperitoneally with 50 mg/kg BW of diethylnitrosamine (DEN) (Sigma).
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA from all the samples was purified using the Qiagen RNeasy purification kit following the manufacturer’s protocol.
|
| Label |
biotin
|
| Label protocol |
The integrity of the RNA was measured using a Bioanalyser and RIN values > 7-8 were considered adequate to proceed further with total RNA transcription into cRNA using the Illumina Total Prep RNA amplification kit (Ambion) following the manufacturer’s protocol.
|
| |
|
| Hybridization protocol |
Biotinylated cRNA was hybridized to Illumina MouseRef8v2 bead chips.
|
| Scan protocol |
Gene expression matrices were scanned using Illumina iSCAN Control Software.
|
| Description |
30 mg/Kg BW
|
| Data processing |
Data was quantile normalized with background subtraction using Illumina BeadStudio.
|
| |
|
| Submission date |
Apr 09, 2012 |
| Last update date |
Jul 12, 2012 |
| Contact name |
Manway Liu |
| E-mail(s) |
manway.liu@novartis.com
|
| Organization name |
Novartis Institutes for Biomedical Research
|
| Street address |
250 Massachusetts Avenue
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02139 |
| Country |
USA |
| |
|
| Platform ID |
GPL6885 |
| Series (1) |
| GSE37129 |
mTOR inhibitors synergistically induce regression, reversal of gene expression and autophagy in hepatocellular carcinoma |
|
